Investigational drug · Phase 3
VE303
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "VE303"
First trial start
2024
May 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VE303", any sponsor or status.
Conditions studied
As listed on its trial records.
- Clostridium Difficile
- Clostridium Difficile Infections
- Clostridium Difficile Infection Recurrence
- Clostridioides Difficile Infection
- Clostridioides Difficile Infection Recurrence
- CDI
- C. Diff Infection
- Recurrent Clostridium Difficile Infection
- C.Difficile Diarrhea
- Diarrhea Infectious
Approved drugs for the same conditions: C. difficile infection · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VE303" as an intervention, largest first.
- VE303 for Prevention of Recurrent Clostridioides Difficile InfectionPivotal-lookingRecruiting
Vedanta Biosciences, Inc.Industry
NCT06237452 · 852 participants (planned) · Start May 20, 2024 · Primary completion Jun 2027
Drug: VE303; Placebo · For: Clostridium Difficile; Clostridium Difficile Infections; Clostridium Difficile Infection Recurrence and 7 more
Sites: Huntsville, Alabama; Chandler, Arizona; Phoenix, Arizona · 215 sites in all
Vedanta Biosciences, Inc.Industry
NCT03788434 · 79 participants · Start Feb 8, 2019 · Primary completion Jun 2, 2021
Drug: VE303; Placebo · For: Clostridium Difficile Infection Recurrence; Clostridium Difficile Infection; Clostridium Difficile and 4 more
Sites: Phoenix, Arizona; Jonesboro, Arkansas; Canoga Park, California · 37 sites in all
Vedanta Biosciences, Inc.Industry
NCT04236778 · 39 participants · Start Nov 28, 2017 · Primary completion Mar 11, 2019
Drug: VE303; Oral Vancomycin · For: Healthy Volunteers
Sites: Baltimore, Maryland
Patricia BloomAcademic, hospital or other
NCT04899115 · 19 participants · Start Aug 6, 2021 · Primary completion Apr 10, 2023
Drug: Placebo; VE303 and 1 more · For: Cirrhosis; Hepatic Encephalopathy
Sites: Ann Arbor, Michigan
Newest research
PubMed records naming it or its code names, newest first.
- New investigational agents for the treatment of Clostridioides difficile infections.
Tran MN, Eubank TA, Kullar R, et al. · Expert Opin Investig Drugs 2025
- What's New and What's Next in Fecal Microbiota Transplantation?
Baydoun H, Hussain N, Wu KO, et al. · Biologics 2025
- Fecal microbiota transplantation: present and future.
Cha RR, Sonu I · Clin Endosc 2025
- The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.
Berry P, Khanna S · Indian J Gastroenterol 2025
- Safety and efficacy of a defined bacterial consortium, VE303, to treat HE.
Bloom PP, Bassis CM, Crossette E, et al. · Hepatol Commun 2025
- Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection.
Menon R, Bhattarai SK, Crossette E, et al. · Nat Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.